KING ABDULLAH MEDICAL CITY

The GCC pharmaceutical market, led by Saudi Arabia, is rapidly expanding due to factors like population growth and lifestyle diseases. The market is expected to exceed US$ 12 Billion by 2030, with branded and imported drugs dominating. Clinical trials in the region involve over 250 drugs, and healthcare transformation programs are driving growth. Local manufacturing is increasing, especially in generics and biosimilars, while digital health innovations are enhancing market efficiency.